Immunologic mechanisms in granulomatous lung disease

Publisher： Elsevier

ISSN： 0162-3109

Source： Immunopharmacology, Vol.48, Iss.3, 2000-07, pp. : 329-331

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Adalimumab/etanercept/infliximab: Pulmonary nodulosis and aseptic granulomatous lung disease: 11 case reports

Reactions Weekly, Vol. 1, Iss. 1292, 2010-01 ,pp. : 4-5

Adis International

Access to resources Recommend Favorite

Advanced Neoplastic Disease as Immunologic, Endocrine and Metabolic Disorder

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents), Vol. 10, Iss. 4, 2011-08 ,pp. : 248-261

Bentham Science Publishers

Access to resources Recommend Favorite

Etanercept: Pulmonary granulomatous disease: 4 case reports

Reactions Weekly, Vol. 1, Iss. 1244, 2009-01 ,pp. : 17-18

Adis International

Access to resources Recommend Favorite

Adalimumab: Chronic granulomatous disease: case report

Reactions Weekly, Vol. 1, Iss. 1159, 2007-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Current treatment options for chronic granulomatous disease

By Goldblatt David

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 7, 2002-07 ,pp. : 857-863

Informa Healthcare

Access to resources Recommend Favorite